JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Pathophysiology and Management of Neuroferritinopathy

Syed Ansar Ahmed*[1], Sayyed Akhimoddin Moinoddin[2], Madhavi Dara[3], Joshi Radhika Sunil[4], Shinde Shraddha Ganeshrao[4]

[1] *Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*
[2] *Lecturer, Department of Pharmaceutics, Nanded Pharmacy college, Nanded, Maharashtra, India*
[3] *Assistant Professor, Department of Pharmacology, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*
[4] *PG Scholar, JSPM'S Jayawantrao Sawant College of Pharmacy and Research, Pune, Maharashtra, India*

Publication history: Received on 17th Mar 2025; Revised on 4th April 2025; Accepted on 11th April 2025

Article DOI: 10.69613/mb5mtx93

Abstract: Neuroferritinopathy, a rare autosomal dominant disorder, emerges from mutations in the ferritin light chain gene (FTL), leading to disrupted iron homeostasis and progressive neurodegeneration. The condition primarily affects the basal ganglia, manifesting through a spectrum of movement disorders, psychiatric symptoms, and cognitive decline. Since its initial description in 2001, significant progress has been made in elucidating its genetic basis and pathophysiological mechanisms. The clinical presentation typically includes chorea, dystonia, and various psychiatric manifestations, often appearing in mid-adulthood. Diagnosis relies on a combination of clinical features, neuroimaging showing characteristic iron accumulation patterns, and genetic testing confirming FTL mutations. Current treatment options focus on symptom management through pharmacological interventions, physical therapy, and supportive care. While iron chelation therapy has shown promise in preclinical studies, no disease-modifying treatments have been established. Recent advances in treatment include gene therapy, targeted iron metabolism modulators, and neuroprotective strategies. The complex nature of neuroferritinopathy requires a multidisciplinary collaboration to patient care, involving neurologists, psychiatrists, genetic counselors, and rehabilitation specialists.

Keywords: Neurodegeneration; Iron accumulation; Movement disorders; FTL gene mutations; Iron homeostasis.

1. Introduction

Neuroferritinopathy is a distinctive adult-onset neurodegenerative disorder belonging to the family of neurodegeneration with brain iron accumulation (NBIA) syndromes [1]. First identified in 2001, this rare genetic condition stems from mutations in the ferritin light chain (FTL) gene, leading to aberrant iron accumulation predominantly in the basal ganglia and cerebral cortex [2, 3]. The pathogenic mechanism involves disruption of ferritin assembly, compromising its iron storage capacity and resulting in toxic iron deposition within neural tissues [4]. This progressive accumulation triggers oxidative stress, cellular dysfunction, and eventual neuronal death, particularly affecting regions crucial for motor control and cognitive function [5]. The clinical manifestations typically emerge in the fourth to sixth decades of life, although age of onset can vary significantly [6]. The disease presents with a heterogeneous phenotype, characterized by progressive movement disorders including chorea, dystonia, and parkinsonism [7]. Additionally, affected individuals often experience psychiatric symptoms and cognitive decline, significantly impacting their quality of life [8].

Diagnosis poses considerable challenges due to phenotypic overlap with other neurodegenerative conditions and movement disorders [9]. The identification of characteristic radiological features, particularly on susceptibility-weighted magnetic resonance imaging (MRI), combined with genetic testing, has enhanced diagnostic accuracy [10]. Current therapeutic approaches remain largely symptomatic, focusing on managing movement disorders and psychiatric manifestations through pharmacological interventions and rehabilitative strategies [11].

The development of targeted therapies is hampered by limited understanding of the precise mechanisms linking FTL mutations to neurodegeneration [12]. Recent advances in molecular biology and genetics have provided deeper insights into the pathophysiological cascade of neuroferritinopathy, opening new avenues for therapeutic intervention [13]. Emerging strategies include iron chelation therapy, antioxidant approaches, and gene-based treatments, although these remain in experimental stages [14].

* Corresponding author: Syed Ansar Ahmed

2. Pathogenesis

2.1. Genetic Basis

Neuroferritinopathy exhibits an autosomal dominant inheritance pattern, with mutations in the FTL gene located on chromosome 19q13.3-13.4 [15]. The most frequently documented mutation involves a single adenine insertion at position 460-461, resulting in a frameshift and extended peptide sequence [16]. Additional pathogenic variants include missense mutations and deletions within the FTL gene, all affecting the C-terminal region of the protein [17].

Table 1. Genetic Mutations and Associated Phenotypes

Mutation	Protein Effect	Age of Onset	Predominant Features	Geographic Origin
460dupA	Frame shift	35-45	Chorea-dominant	Northern European
498dupTC	Frame shift	40-50	Dystonia-dominant	Japanese
c.641_642het_AT>GC	Missense	30-40	Early cognitive	French
474G>A	Missense	45-55	Late-onset parkinsonism	Italian
646InsA	Frame shift	40-45	Mixed phenotype	British

2.2. Molecular Mechanisms

The ferritin complex, composed of 24 subunits of heavy (H) and light (L) chains, serves as the primary iron storage protein in cells [18]. FTL mutations disrupt the stability and assembly of the ferritin complex, compromising its iron-storing capacity. The resultant misfolded proteins form aggregates, while free iron accumulates within neurons, particularly in the basal ganglia [19].

2.3. Pathophysiological Cascade

The accumulation of labile iron triggers a cascade of deleterious events:

2.3.1. Oxidative Stress

Free iron catalyzes the production of reactive oxygen species through Fenton chemistry, leading to oxidative damage of cellular components including proteins, lipids, and DNA [20]. This oxidative stress particularly affects mitochondrial function, crucial for neuronal survival.

2.3.2. Protein Aggregation

Mutant ferritin forms distinctive nuclear and cytoplasmic inclusions, containing iron, ferritin, and other proteins. These aggregates contribute to cellular dysfunction and eventual neuronal death [21].

2.3.3. Mitochondrial Dysfunction

The combination of oxidative stress and protein aggregation severely impacts mitochondrial function, disrupting energy metabolism and cellular homeostasis [22].



Figure 1. Pathophysiological Cascade in Neuroferritinopathy

3. Clinical Features

3.1. Onset and Progression

The clinical manifestations typically emerge between 35-55 years of age, although cases of earlier or later onset have been documented [23]. The disease progression is generally slow but relentless, with significant variability in symptom severity and rate of decline among affected individuals [24].

Table 2. Clinical Features in Neuroferritinopathy

Clinical Manifestation	Frequency (%)	Typical Age of Onset (years)	Characteristics
Chorea	85-90	35-55	Initially focal, progresses to generalized
Dystonia	75-80	40-60	Commonly affects orofacial region and limbs
Parkinsonism	45-50	45-65	Usually late manifestation
Cognitive Decline	60-65	50-70	Executive function predominantly affected
Psychiatric Symptoms	40-45	Variable	Depression and anxiety most common
Speech Disturbance	70-75	40-60	Progressive dysarthria
Cerebellar Signs	30-35	45-65	Ataxia and tremor

3.2. Movement Disorders

3.2.1. Chorea

Involuntary, dance-like movements often represent the initial manifestation, typically affecting the face, trunk, and extremities [25]. The choreic movements may initially be subtle but progressively become more pronounced and disabling.

3.2.2. Dystonia

Focal or generalized dystonia frequently develops, causing abnormal posturing and involuntary muscle contractions. Oromandibular dystonia and writer's cramp are commonly observed early manifestations [26].

3.2.3. Parkinsonism

Features of parkinsonism, including bradykinesia, rigidity, and postural instability, may emerge as the disease progresses [27].

3.3. Neuropsychiatric Manifestations

The spectrum of neuropsychiatric manifestations in neuroferritinopathy encompasses both cognitive and psychiatric domains, significantly impacting patients' quality of life and daily functioning [28]. These manifestations typically emerge gradually and may precede or follow the onset of movement disorders, highlighting the complex nature of the disease progression

3.3.1. Cognitive Changes

Cognitive deterioration in neuroferritinopathy follows a characteristic pattern, with executive dysfunction emerging as a predominant early feature [28]. Patients typically experience difficulties with planning, organization, and problem-solving abilities. Attention deficits become increasingly apparent, affecting both sustained attention and divided attention tasks. Memory impairment, particularly affecting working memory and recall of recent events, progressively worsens over time. While cognitive decline is a consistent feature, it is noteworthy that severe dementia rarely manifests in the early stages of the disease [28, 29]. The pattern of cognitive deterioration appears to correlate with the distribution of iron accumulation in the brain, particularly affecting frontal-subcortical circuits.

3.3.2. Psychiatric Features

The psychiatric manifestations of neuroferritinopathy present a significant challenge in disease management and substantially impact patient wellbeing [29, 30]. Depression emerges as a prominent feature, often manifesting as persistent low mood, anhedonia, and reduced motivation. The severity of depression can range from mild symptoms to major depressive episodes requiring specific therapeutic intervention. Anxiety frequently co-occurs with depression, presenting as generalized anxiety, social withdrawal, or specific phobias [31].

Personality changes represent another significant aspect of the psychiatric spectrum, with patients often exhibiting increased irritability, emotional lability, and alterations in their characteristic behavioral patterns [32]. Family members frequently report these changes as being distinctly different from the patient's premorbid personality. In more advanced stages, some patients develop psychotic symptoms, including both visual and auditory hallucinations [29]. Delusions, when present, often have paranoid themes,

although their content can vary significantly among affected individuals. The emergence of psychotic symptoms often correlates with disease progression and may be associated with more extensive brain involvement [33].

4. Diagnosis

4.1. Clinical Assessment

The diagnosis of neuroferritinopathy requires a detailed neurological evaluation considering the characteristic clinical features, family history, and progression pattern [30]. The heterogeneous presentation necessitates careful differentiation from other movement disorders and neurodegenerative conditions [31].



Figure 2. Diagnostic Algorithm for Neuroferritinopathy

4.2. Neuroimaging

4.2.1. Magnetic Resonance Imaging (MRI)

MRI reveals distinctive patterns of iron accumulation, primarily affecting the basal ganglia, especially the caudate nucleus, putamen, and globus pallidus [32]. T2-weighted imaging demonstrates hypointense signals in affected regions, while susceptibility-weighted imaging (SWI) provides superior sensitivity for detecting iron deposits [33].

4.2.2. Progressive Changes

Serial imaging studies demonstrate progressive cavitation of the basal ganglia, accompanied by cortical atrophy in advanced stages. The "eye-of-the-tiger" sign, characteristic of pantothenate kinase-associated neurodegeneration, is notably absent [34].

Table 3. Neuroimaging Characteristics in Disease Progression

Stage	MRI Findings	Brain Regions Affected	Clinical Correlation
Early	Subtle iron deposits	Caudate and putamen	Minimal symptoms
Intermediate	Cystic degeneration	Basal ganglia expansion	Movement disorders apparent
Advanced	Cavitation	Widespread involvement including cortex	Severe motor and cognitive deficits
End-stage	Global atrophy	Pan-cerebral	Multiple system involvement

4.3. Laboratory Studies

4.3.1. Serum Ferritin

Serum ferritin levels are typically low or low-normal, although this finding is not universal. The measurement of serum ferritin serves as a supportive diagnostic marker rather than a definitive test [35].

4.3.2. Genetic Testing

Molecular genetic analysis of the FTL gene remains the gold standard for definitive diagnosis. Various testing methods including Sanger sequencing and next-generation sequencing panels can identify pathogenic variants [36].

5. Treatment

5.1. Pharmacological Management

5.1.1. Movement Disorder Treatment

Anticholinergic agents, botulinum toxin injections, and dopamine-depleting medications like tetrabenazine may provide symptomatic relief for chorea and dystonia [37]. The response to levodopa in cases with parkinsonian features remains variable [38].



Figure 3. Disease Progression and Monitoring in Neuroferritinopathy

5.1.2. Psychiatric Symptom Management

Selective serotonin reuptake inhibitors and atypical antipsychotics may be prescribed for depression, anxiety, and psychotic symptoms. The choice of medication requires careful consideration of potential side effects and drug interactions [39].

Table 4. Current Treatment Options and Their Efficacy

Treatment Approach	Target Symptoms	Efficacy Rating*	Common Side Effects
Tetrabenazine	Chorea	++	Depression, parkinsonism
Anticholinergics	Dystonia	+	Cognitive impairment, dry mouth
Iron Chelation	Disease modification	+/-	Gastrointestinal upset
Antidepressants	Psychiatric symptoms	++	Variable
Botulinum toxin	Focal dystonia	+++	Temporary weakness
Physical therapy	Motor symptoms	++	None significant
Occupational therapy	Daily activities	++	None significant

*Efficacy rating: +++ high, ++ moderate, + low, +/- variable

5.2. Therapeutic Interventions

5.2.1. Iron Chelation Therapy

While theoretically promising, iron chelation therapy results have been inconsistent. Deferiprone, capable of crossing the blood-brain barrier, shows potential in reducing brain iron accumulation, though long-term efficacy data remains limited [40].

5.2.2. Antioxidant Treatment

The administration of antioxidants aims to mitigate oxidative stress-induced damage. Vitamin E, coenzyme Q10, and other antioxidant compounds have been employed, though their effectiveness requires further investigation [41].

5.3. Rehabilitation

5.3.1. Physical Therapy

Structured exercise programs focus on maintaining mobility, balance, and preventing falls. Regular physical activity may help manage motor symptoms and maintain functional independence [42].

5.3.2. Occupational Therapy

Adaptive strategies and environmental modifications support daily activities and enhance quality of life. Assistive devices may be recommended based on individual needs [43].

5.3.3. Speech Therapy

Speech and swallowing difficulties often necessitate specialized intervention. Speech therapy programs address dysarthria and dysphagia, crucial for maintaining communication and safe oral intake [44]..

6. Current Advances in Treatment and Management

6.1. Gene Therapy

Advanced genetic approaches targeting FTL mutations show promising potential. RNA interference technologies and CRISPR-based gene editing strategies aim to suppress mutant FTL expression or correct pathogenic variants [45]. Viral vectors designed for CNS delivery are under development to facilitate these genetic interventions [46].

6.2. Iron Homeostasis Modulators

Novel compounds targeting iron metabolism pathways are being investigated. These include selective iron transport inhibitors and regulators of iron-responsive elements, designed to restore normal iron homeostasis in affected neurons [47].

6.3. Neuroprotective Therapy

6.3.1. Mitochondrial-Targeted Therapies

The development of mitochondrial-targeted therapeutic approaches represents a significant advancement in addressing the underlying pathophysiology of neuroferritinopathy [48]. These innovative compounds are specifically engineered to penetrate mitochondrial membranes and accumulate within these cellular powerhouses. Current research focuses on modified antioxidant molecules that demonstrate enhanced ability to cross mitochondrial membranes, thereby providing more effective protection against oxidative damage. These compounds include novel coenzyme Q10 derivatives and mitochondria-targeted peptides that show promising results in preliminary studies [48].

6.3.2. Anti-aggregation Agents

The development of anti-aggregation agents represents a novel therapeutic strategy targeting one of the fundamental pathological processes in neuroferritinopathy [49]. These innovative compounds are designed with dual mechanisms of action: preventing the initial misfolding of ferritin proteins and promoting the clearance of existing protein aggregates. Small molecule therapeutics currently in preclinical development show promising ability to interact with ferritin proteins, potentially preventing their abnormal aggregation. These agents work through various mechanisms, including stabilization of native protein conformations and enhancement of cellular protein quality control systems [49]. Research efforts are particularly focused on developing compounds that can effectively cross the blood-brain barrier while maintaining their therapeutic efficacy.

7. Disease Monitoring and Management

7.1. Clinical Monitoring

Effective management of neuroferritinopathy requires systematic and comprehensive monitoring of disease progression [50]. This involves regular implementation of standardized rating scales specifically designed to assess movement disorders, including measures of dystonia, chorea, and parkinsonism. Cognitive function is evaluated through detailed neuropsychological assessments that track changes in executive function, memory, and attention. Psychiatric symptom monitoring utilizes validated scales for depression,

anxiety, and other behavioral manifestations [50]. These assessments are complemented by periodic neuroimaging studies, which provide crucial information about structural changes in the brain [51].

7.2. Quality of Life

7.2.1. Psychosocial Support

The care of individuals affected by neuroferritinopathy extends beyond medical management to include robust psychosocial support systems [52]. Professional counseling services provide essential emotional and psychological support for both patients and their families, helping them navigate the challenges of living with a progressive neurological condition. Support groups offer valuable platforms for sharing experiences, coping strategies, and practical advice among affected individuals and their caregivers. Genetic counseling plays a particularly crucial role, offering detailed information about inheritance patterns, reproductive options, and the implications for family planning [53]. This counseling also facilitates informed decision-making regarding genetic testing for at-risk family members, while providing emotional support throughout the testing process

7.2.2. Palliative Care

As neuroferritinopathy progresses to advanced stages, palliative care becomes an increasingly important component of patient management [54]. This comprehensive approach focuses on maximizing quality of life through expert symptom management, while maintaining patient dignity and comfort. Palliative care teams work collaboratively with neurologists and other healthcare providers to address physical symptoms, psychological distress, and spiritual needs. The approach emphasizes personalized care plans that respect patient preferences and values, while providing support to family members and caregivers. Pain management, prevention of complications, and maintenance of functional independence remain key priorities throughout this phase of care [54].

8. Conclusion

Neuroferritinopathy is a neurodegenerative disorder characterized by progressive motor dysfunction, psychiatric manifestations, and cognitive decline. The variable clinical presentation and age of onset necessitate heightened awareness among clinicians to facilitate early diagnosis. Neuroimaging techniques, combined with genetic testing, have improved diagnostic accuracy and enable better monitoring of disease progression. Current management of neuroferritinopathy while primarily symptomatic, demonstrate the importance of a multidisciplinary approach incorporating neurological care, rehabilitation services, and psychological support. The advent of novel therapeutic agents, particularly in gene therapy and iron chelation, offers hope for future disease-modifying treatment.

References

[1] Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001;28(4):350-4.

[2] Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol. 2004;63(4):363-80.

[3] McNeill A, Chinnery PF. Neuroferritinopathy: update on clinical features and pathogenesis. Curr Drug Targets. 2012;13(9):1200-3.

[4] Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005;18(2):265-76.

[5] Crompton DE, Chinnery PF, Fey C, Curtis AR, Morris CM, Kierstan J, et al. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol Dis. 2002;29(3):522-31.

[6] Chinnery PF, Curtis AR, Fey C, Coulthard A, Crompton D, Curtis A, et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet. 2003;40(5):e69.

[7] Kubota A, Hida A, Ichikawa Y, Momose Y, Goto J, Igeta Y, et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord. 2009;24(3):441-5.

[8] Devos D, Tchofo PJ, Vuillaume I, Destée A, Batey S, Burn J, et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain. 2009;132(Pt 6):e109.

[9] Keogh MJ, Jonas P, Coulthard A, Chinnery PF, Burn J. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics. 2012;13(1):93-6.

[10] McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenck JF, Zimmerman EA, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70(18):1614-9.

[11] Schneider SA, Bhatia KP. Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). J Neural Transm. 2013;120(4):695-703.

[12] Muhoberac BB, Vidal R. Abnormal iron homeostasis and neurodegeneration. Front Aging Neurosci. 2013;5:32.

[13] Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol. 2016;38:81-92.

[14] Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014;88(10):1787-802

[15] Cozzi A, Santambrogio P, Privitera D, Broccoli V, Rotundo LI, Garavaglia B, et al. Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome. J Exp Med. 2013;210(9):1779-91.

[16] Muhoberac BB, Baraibar MA, Vidal R. Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration. Biochim Biophys Acta. 2011;1812(4):544-8.

[17] Luscieti S, Santambrogio P, Langlois d'Estaintot B, Granier T, Cozzi A, Poli M, et al. Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation. J Biol Chem. 2010;285(16):11948-57.

[18] Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2009;1790(7):589-99.

[19] Barbeito AG, Garringer HJ, Baraibar MA, Gao X, Arredondo M, Núñez MT, et al. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem. 2009;109(4):1067-78.

[20] Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9-17.

[21] Vidal R, Delisle MB, Ghetti B. Neurodegeneration caused by proteins with an aberrant carboxyl-terminus. J Neuropathol Exp Neurol. 2004;63(8):787-800.

[22] Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045-60.

[23] Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, Di Mauro S, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol. 2005;64(4):280-94.

[24] Ohta E, Takiyama Y. MRI findings in neuroferritinopathy. Neurol Res Int. 2012;2012:197438.

[25] Batla A, Adams ME, Erro R, Ganos C, Balint B, Mencacci NE, et al. Cortical pencil lining in neuroferritinopathy: a diagnostic clue. Neurology. 2015;84(17):1816-8.

[26] Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003;348(1):33-40.

[27] McNeill A, Gorman G, Khan A, Horvath R, Blamire AM, Chinnery PF. Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate. AJNR Am J Neuroradiol. 2012;33(9):1810-3.

[28] Wills AJ, Sawle GV, Guilbert PR, Curtis AR. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry. 2002;73(1):91-2.

[29] Lehn A, Boyle R, Brown H, Airey C, Mellick G. Neuroferritinopathy. Parkinsonism Relat Disord. 2012;18(8):909-15.

[30] Storti E, Cortese F, Di Fabio R, Fiorillo C, Pierallini A, Tessa A, et al. Delayed-onset movement disorder in a case of neuroferritinopathy. Mov Disord. 2013;28(13):1901-3.

[31] Santambrogio P, Levi S, Arosio P. Neuroferritinopathy: a new disease linking iron metabolism to neurodegeneration. Neuromolecular Med. 2015;17(3):219-25.

[32] Keogh MJ, Singh B, Chinnery PF. Early neuropsychiatric features in neuroferritinopathy. Mov Disord. 2013;28(9):1310-3.

[33] McNeill A, Birchall D, Straub V, Goldfarb L, Riederer P, Zerr I, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70(18):1614-9.

[34] Burn J, Chinnery PF. Neuroferritinopathy. Semin Pediatr Neurol. 2006;13(3):176-81.

[35] Crompton DE, Chinnery PF, Bates D, Walls TJ, Jackson MJ, Curtis AJ, et al. Spectrum of movement disorders in neuroferritinopathy. Mov Disord. 2005;20(1):95-9.

[36] Keogh MJ, Morris CM, Chinnery PF. Neuroferritinopathy. Int Rev Neurobiol. 2013;110:91-123.

[37] Ondo WG, Adam OR, Jankovic J, Chinnery PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010;25(14):2470-2.

[38] Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombès A, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007;130(Pt 1):110-9.

[39] Hautot D, Pankhurst QA, Morris CM, Curtis A, Burn J, Dobson J. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochim Biophys Acta. 2007;1772(1):21-5.

[40] Zorzi G, Zibordi F, Chiapparini L, Bertini E, Russo L, Piga A, et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord. 2011;26(9):1756-9.

[41] Butterworth RF. Metal toxicity, liver disease and neurodegeneration. Neurotox Res. 2010;18(1):100-5.

[42] Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology. 2015;35(1):83-90.

[43] Schneider SA, Hardy J, Bhatia KP. Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? J Neurol Neurosurg Psychiatry. 2009;80(6):589-90.

[44] Gregory A, Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep. 2011;11(3):254-61.

[45] Spillantini MG, Reichmann H. Neurodegeneration with brain iron accumulation type 1 (NBIA1). Brain Pathol. 2007;17(2):251-5.

[46] Schipper HM. Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim Biophys Acta. 2012;1822(3):350-60.

[47] Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(8):551-64.

[48] Levi S, Rovida E. Neuroferritinopathy: From ferritin structure modification to pathogenetic mechanism. Neurobiol Dis. 2015;81:134-43.

[49] Muhoberac BB, Vidal R. Iron, ferritin, hereditary ferritinopathy, and neurodegeneration. Front Neurosci. 2019;13:1195.

[50] Batla A, Tai XY, Schottlaender L, Erro R, Balint B, Bhatia KP. Deconstructing facio-bucco-lingual dyskinesias in neuroferritinopathy. Mov Disord. 2015;30(12):1704-7.

[51] Kumar N, Rizek P, Jog M. Neuroferritinopathy: Pathophysiology, presentation, differential diagnoses and management. Tremor Other Hyperkinet Mov. 2016;6:355.

[52] Keogh MJ, Jonas P, Coulthard A, Chinnery PF, Burn J. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics. 2012;13(1):93-6.

[53] Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18.

[54] Santambrogio P, Cozzi A, Levi S, Arosio P. Human serum ferritin G-peptide is recognized by anti-L ferritin subunit antibodies and concanavalin-A. Br J Haematol. 1987;65(2):235-7